Impact of etanercept treatment on ultraviolet B-induced inflammation, cell cycle regulation and DNA damage

British Journal of Dermatology

Volumn 164, Issue 1, 2011, Pages 110-115

  Gambichler, T ^a   Tigges, C ^a   Dith, A ^a   Skrygan, M ^a   Scola, N ^a   Altmeyer, P ^a   Kreuter, A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN D1; DNA; ETANERCEPT; INTERLEUKIN 12; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P53; SURVIVIN; THYMINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE REGULATION; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED CLINICAL TRIAL; DNA DAMAGE; ERYTHEMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MONOTHERAPY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PSORIASIS; PUNCH BIOPSY; RISK ASSESSMENT; SKIN BIOPSY; SKIN INFLAMMATION; TREATMENT INDICATION; ULTRAVIOLET B RADIATION;

ADULT; BIOPSY; CELL CYCLE; DNA DAMAGE; ERYTHEMA; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; ULTRAVIOLET RAYS;

EID: 78650443967     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10099.x     Document Type: Article

References (29)

1. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006; 10: 1-252. (Pubitemid 44911257)
2. Boonstra A, Savelkoul HF,. The role of cytokines in ultraviolet-B induced immunosuppression. Eur Cytokine Netw 1997; 8: 117-23. (Pubitemid 28152137)
3. Di Lernia V, Albertini G,. Is antitumour necrosis factor therapy combined with ultraviolet B phototherapy safe? Br J Dermatol 2010; 162: 1147-8.
4. Chakravarty EF, Michaud K, Wolfe F,. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130-5. (Pubitemid 41587856)
5. Sheppard J, Raza K, Buckley CD,. Skin cancer in psoriatic arthritis treated with anti-TNF therapy. Rheumatology 2007; 46: 1623-4. (Pubitemid 47500587)
6. Wolf P, Hofer A, Legat FJ, et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol 2009; 160: 186-9.
7. Kircik L, Bagel J, Korman N, et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008; 7: 245-53.
8. Gambichler T, Kreuter A, Scola N, et al. Etanercept plus narrowband UVB phototherapy is superior to etanercept monotherapy of psoriasis. In: Psoriasis 2010-Congress of the Psoriasis International Network, Paris 1-4 July, Abstract book PSO2010-216.
9. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
10. Gambichler T, Moussa G, Tomi NS, et al. Reference limits for erythema-effective UV doses. Photochem Photobiol 2006; 82: 1097-102. (Pubitemid 44450197)
11. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000; 34: 161-4.
12. Fullerton A, Fischer T, Lahit A, et al. Guidelines for measurement of skin color and erythema. A report from the standardization group of the European Society of Contact Dermatitis. Contact Dermatitis 1996; 35: 1-10.
13. Hussein MR,. Ultraviolet radiation and skin cancer: molecular mechanisms. J Cutan Pathol 2005; 32: 191-205. (Pubitemid 40278816)
14. Young AR, Chadwick CA, Harrison GI, et al. Wavelength dependence for DNA photodamage in human skin in vivo. Radiat Prot Dosimetry 2000; 91: 73-5.
15. Burren R, Scaletta C, Frenk E, et al. Sunlight and carcinogenesis: expression of p53 and pyrimidine dimers in human skin following UVA I, UVA I + II and solar simulating radiations. Int J Cancer 1998; 76: 201-6. (Pubitemid 28180373)
16. Yarosh DB, Boumakis S, Brown AB, et al. Measurement of UVB-induced DNA damage and its consequences in models of immunosuppression. Methods 2002; 28: 55-62.
17. Wang Y, Rosenstein B, Goldwyn S, et al. Differential regulation of p53 and Bcl-2 expression by ultraviolet A and B. J Invest Dermatol 1998; 111: 380-4. (Pubitemid 28400080)
18. Katiyar SK, Matsui MS, Mukhtar H,. Kinetics of UV light-induced cyclobutane pyrimidine dimers in human skin in vivo: an immunohistochemical analysis of both epidermis and dermis. Photochem Photobiol 2000; 72: 788-93.
19. Dallaglio K, Palazzo E, Marconi A, et al. Endogenous survivin modulates survival and proliferation in UVB-treated human keratinocytes. Exp Dermatol 2009; 18: 464-71.
20. Walker SL, Young AR,. An action spectrum (290-320 nm) for TNFalpha protein in human skin in vivo suggests that basal-layer epidermal DNA is the chromophore. Proc Natl Acad Sci USA 2007; 104: 19051-4.
21. Aziz MH, Ghotra AS, Shukla Y, Ahmad N,. Ultraviolet-B radiation causes an upregulation of survivin in human keratinocytes and mouse skin. Photochem Photobiol 2004; 80: 602-8. (Pubitemid 40174492)
22. Benjamin CL, Ullrich SE, Kripke ML, Ananthaswamy HN,. p53 tumor suppressor gene: a critical molecular target for UV induction and prevention of skin cancer. Photochem Photobiol 2008; 8: 55-62.
23. Hiyama H, Reeves SA,. Role for cyclin D1 in UVC-induced and p53-mediated apoptosis. Cell Death Differ 1999; 6: 565-9. (Pubitemid 29292112)
24. Albanese C, D'Amico M, Reutens AT, et al. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 1999; 274: 34186-95. (Pubitemid 129511756)
25. Bacqueville D, Mavon A,. Caspase-3 activation and DNA damage in pig skin organ culture after solar irradiation. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. Photochem Photobiol 2008; 84: 1164-71.
26. Faurschou A, Gniadecki R, Wulf HC,. Infliximab inhibits DNA repair in ultraviolet B-irradiated premalignant keratinocytes. Exp Dermatol 2008; 17: 933-8.
27. Patel RV, Clark LN, Lebwohl M, Weinberg JM,. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60: 1001-17.
28. Berneburg M, Röcken M, Benedix F,. Phototherapy with narrowband vs broadband UVB. Acta Derm Venereol (Stockh) 2005; 85: 98-108. (Pubitemid 40477657)
29. Weischer M, Blum A, Eberhard F, et al. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol (Stockh) 2004; 84: 370-4. (Pubitemid 39312270)